The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy | Arthritis Research & Therapy | Full Text
761037Orig1s000
![Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0]](https://www.lenus.ie/bitstream/handle/10147/628004/COVID-19_Evidence_Review_Group_Tocilizumab_V6_Final_Version.pdf.jpg?sequence=8&isAllowed=y "Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0]")
Rapid Evidence Review: Tocilizumab in the management of patients who have severe COVID-19 infection with suspected hyperinflammation. [v6.0]
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm | Nature Communications
Frontiers | Single-Cell RNA Sequencing of Tocilizumab-Treated Peripheral Blood Mononuclear Cells as an in vitro Model of Inflammation
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group - eClinicalMedicine
Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy - ScienceDirect
Effective treatment of severe COVID-19 patients with tocilizumab | PNAS
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study - The Lancet Rheumatology
Pharmacokinetic /Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19 | medRxiv
Actemra® 20 mg/mL, concentrate for solution for intravenous (IV) infusion
Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells | PLOS ONE
Health Product InfoWatch: October 2022 - Canada.ca
Full article: Tocilizumab (Actemra)
Comparison of the two tocilizumab strategies used in the economic... | Download Scientific Diagram
JCI - IL-6 polymorphisms: a useful genetic tool for inflammation research?
Comparison of the two tocilizumab strategies used in the economic model | Download Scientific Diagram
Cureus | High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial | Article
Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab - Document - Gale OneFile: Health and Medicine
Anti-hIL-6R mAbs | Tocilizumab | InvivoGen
Pharmaceutics | Free Full-Text | Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
LncRNA MIR31HG is induced by tocilizumab and ameliorates rheumatoid arthritis fibroblast-like synoviocyte-mediated inflammation via miR-214-PTEN-AKT signaling pathway | Aging
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine
Unravelling the potentialities of tocilizumab for the development of a potential immunotherapeutic regimen against COVID-19—A narrative review
Tocilizumab reduces deaths in patients hospitalised with COVID-19 — Centre for Tropical Medicine and Global Health
